Richard Pazdur Appointed Director of the FDA’s Drug Center: A New Chapter for Cancer Regulation
oncodaily - Dr. Richard Pazdur, one of the most influential figures in oncology drug regulation, has been appointed Director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and […]
AI Summary: The FDA has ushered in a new era in oncology drug oversight by appointing Dr. Richard Pazdur as the director of its Drug Center. The move comes amid agency challenges and staff cuts, promising stabilizing leadership at one of its most influential divisions.
Canada loses measles elimination status after ongoing outbreaks
go - International health experts say Canada is no longer measles-free because of ongoing outbreaks, as childhood vaccination rates fall and the highly contagious virus spreads across North and South America
AI Summary: Health experts report that Canada has lost its measles elimination status amid large-scale outbreaks and falling vaccination rates. The loss, confirmed by multiple sources, has raised public health alarms and may affect regional disease control efforts.
FDA rolls back warning labels on HRT products for menopause, citing misinformation
fiercehealthcare - The action, announced Monday, follows a comprehensive review of scientific literature by an expert panel at the agency in July, as well as a public comment period, officials said. Pharmas are expected to update and reprint their product labeling to remove…
AI Summary: Following a rigorous review of the scientific evidence, federal regulators are scrapping boxed warnings on hormone replacement products used for menopausal symptom relief. The move—aimed at increasing treatment access—casts a skeptical eye on long-held safety fears, inviting both applause and a few sarcastic raised eyebrows in the industry.
CMS unveils new Medicaid drug payment model
Max Bayer / endpoints - CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...
AI Summary: The Centers for Medicare and Medicaid Services has introduced a novel Medicaid drug payment model that employs a most-favored nation pricing strategy, aiming to rein in healthcare spending. This bold move signals a shift toward competitive pricing that, while promising cost efficiencies, also raises eyebrows over its unorthodox approach.
What Trump’s New Drug Pricing Deal Means for People With Obesity
Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
AI Summary: In a bold move to tackle the obesity crisis, the Trump administration has brokered agreements with industry giants such as Eli Lilly and Novo Nordisk to slash weight-loss drug prices. The deals, promising reductions as steep as $149 a month, have sparked both applause and debate over the future of drug pricing in America.